{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:55:41Z","timestamp":1793350541416,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Autoimmune encephalitis is a neurological disease caused by abnormal autoimmune mechanisms, characterized by a range of symptoms such as psychiatric and behavioral abnormalities, cognitive impairment, memory decline, and seizures. It is primarily identified by the presence of autoantibodies against neuronal surface antigens in the cerebrospinal fluid. This disease is relatively rare in clinical settings, and its diagnosis remains challenging, with fewer than a hundred cases reported to date. Particularly, cases of Anti-DPPX encephalitis presenting with delayed myoclonus and blurred vision are extremely rare. This case report emphasizes the complexity of the diagnosis and the effective treatment of Anti-DPPX encephalitis with delayed myoclonus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>The patient experienced intermittent fever accompanied by severe headaches for one month, with headaches worsening in an upright position, followed by two hours of vomiting, with stomach contents being expelled. Upon admission, the preliminary diagnosis included suspected central nervous system infection and suspected autoimmune encephalitis. Despite receiving anti-infective and antiviral treatments, as well as acid suppressant and gastric protection therapies, the patient\u2019s condition continued to deteriorate. Both computed tomography (CT) and magnetic resonance imaging (MRI) showed no apparent abnormalities. Further cerebrospinal fluid and serum tests revealed the presence of anti-DPPX antibodies, confirming the diagnosis of Anti-DPPX encephalitis. The patient underwent a comprehensive treatment regimen, including high-dose steroid pulse therapy, intravenous immunoglobulin, antiviral and anti-infective therapy, as well as acid suppressant and gastric protection treatments. Significant symptom improvement was observed, and by the 8th day of hospitalization, the condition had stabilized. In the 8th month of follow-up, the patient suddenly developed persistent tremor in both hands, without obvious cause. without a recurrence of fever or consciousness disturbances. Steroid therapy was restarted in combination with eculizumab, which was later switched to ofatumumab treatment. The patient\u2019s symptoms improved compared to before, and re-examination showed DPPX antibody titers had turned negative. Two months post-discharge, follow-up continued, and the patient\u2019s family reported that the tremors persisted, affecting daily life and studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The current patient is the first reported case of Anti-DPPX encephalitis presenting with delayed tremor accompanied by blurred vision. The patient\u2019s condition was quite fluctuating, which led us to discuss the diversity of symptoms as related to extrapyramidal and occipital lobe damage caused by immune-mediated inflammation. Symptom improvement was achieved through a combination of IVMP, eculizumab, and ofatumumab treatments. The prodromal symptoms of Anti-DPPX encephalitis are easily misdiagnosed as infectious diseases due to the heterogeneity of its clinical manifestations. Early identification of the antibody and initiation of immunotherapy can improve the prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1594823","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:46Z","timestamp":1753853506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Treatment of delayed tremor episodes in a patient with DPPX antibody encephalitis"],"prefix":"10.3389","volume":"16","author":[{"given":"Miao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinSheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunQiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2013pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24200","article-title":"Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms","volume":"76","author":"Irani","year":"2014","journal-title":"Ann Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1073\/pnas.89.1.197","article-title":"Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family","volume":"89","author":"Wada","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0896-6273(02)01185-6","article-title":"The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels","volume":"37","author":"Nadal","year":"2003","journal-title":"Neuron"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003796","article-title":"DPPX antibody-associated encephalitis: Main syndrome and antibody effects","volume":"88","author":"Hara","year":"2017","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh526","article-title":"Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates","volume":"128","author":"Ances","year":"2005","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000130","article-title":"Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome","volume":"2","author":"Byrne","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2004.04.019","article-title":"Corticosteroids treatment","volume":"223","author":"Pozzilli","year":"2004","journal-title":"J Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac166","article-title":"Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes","volume":"145","author":"Lee","year":"2022","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12883-022-02649-7","article-title":"Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11698-y","article-title":"Sleep disturbances associated with DPPX autoantibodies: a case series","volume":"270","author":"Gadoth","year":"2023","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1091688","article-title":"Case report: Pain in anti-DPPX encephalitis","volume":"13","author":"Bjerknes","year":"2022","journal-title":"Front Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuron.2006.03.010","article-title":"The kv4.2 potassium channel subunit is required for pain plasticity","volume":"50","author":"Hu","year":"2006","journal-title":"Neuron"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1379933","article-title":"Expanding the clinical spectrum of anti-DPPX encephalitis: a multicenter retrospective study","volume":"18","author":"Gao","year":"2024","journal-title":"Front Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200350","article-title":"Clinical and paraclinical characterizations, management, and prognosis in DPPX antibody-associated encephalitis: A systematic review","volume":"12","author":"Li","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23088","article-title":"Definition and classification of hyperkinetic movements in childhood","volume":"25","author":"Sanger","year":"2010","journal-title":"Mov Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.03.015","article-title":"Clinical approach to tremor in children","volume":"59","author":"Torres-Russotto","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312275.04260.a0","article-title":"Clinical spectrum of voltage-gated potassium channel autoimmunity","volume":"70","author":"Tan","year":"2008","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex428","article-title":"Ophthalmic manifestations of giant cell arteritis","volume":"57","author":"Vodopivec","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00442","article-title":"Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis","volume":"8","author":"Platt","year":"2017","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.363824","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regener Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B33","unstructured":"A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients with Generalized Myasthenia Gravis. [Clinical trial registration]. clinicaltrials.gov\n          \n          \n          \n          2025"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2165\/11203850-000000000-00000","article-title":"Ofatumumab","volume":"70","author":"Sanford","year":"2010","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01178-4","article-title":"Antibody therapies in autoimmune encephalitis","volume":"19","author":"Smets","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1320608","article-title":"Case report: Ofatumumab treatment in anti-DPPX autoimmune encephalitis","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2990.2012.01306.x","article-title":"Review: microglia of the aged brain: primed to be activated and resistant to regulation","volume":"39","author":"Norden","year":"2013","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature23672","article-title":"A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease","volume":"549","author":"Mass","year":"2017","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1594823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:31:49Z","timestamp":1753853509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1594823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1594823"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1594823","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1594823"}}